Suppr超能文献

日本 JMDC 理赔数据库中中重度哮喘患者的患病率及临床特征。

Prevalence and Clinical Characteristics of Patients with Moderate-to-Severe Asthma in Japan Using a JMDC Claims Database.

机构信息

Novartis Pharma K.K., Tokyo, Japan.

JMDC Inc., Tokyo, Japan.

出版信息

Int Arch Allergy Immunol. 2023;184(7):698-706. doi: 10.1159/000528987. Epub 2023 Feb 16.

Abstract

INTRODUCTION

Although the prevalence and burden of asthma are continuously increasing, there is a lack of evidence on the landscape of moderate-to-severe asthma in Japan. Here, we report the prevalence of moderate-to-severe asthma and describe patient's demographics and clinical characteristics from 2010 to 2019 using the JMDC claims database.

METHODS

Patients (≥12 years) from the JMDC database with ≥2 asthma diagnoses in 2 different months in each index year were stratified as moderate-to-severe asthma based on the definition of asthma prevention and management guideline (Japanese Guidelines for Asthma, JGL) or Global Initiative for Asthma (GINA).

PRIMARY OBJECTIVE

10-year trend (2010-2019) in the prevalence of moderate-to-severe asthma.

SECONDARY OBJECTIVE

Demographics and clinical characteristics of patients from 2010 to 2019.

RESULTS

Of 7,493,027 patients from the JMDC database, 38,089 and 133,557 were included in JGL and GINA cohorts, respectively, by 2019. Both cohorts presented an increasing trend in the prevalence rate of moderate-to-severe asthma from 2010 to 2019, irrespective of age groups. Demographics and clinical characteristics were consistent across the cohorts in each calendar year. Majority of patients were in the age group of 18-60 years in both JGL (86.6%) and GINA (84.2%) cohorts. Allergic rhinitis was the most frequent comorbidity and anaphylaxis the least frequent comorbidity reported in both the cohorts.

CONCLUSIONS

In Japan, the prevalence rate of patients with moderate-to-severe asthma, as per JGL or GINA in the JMDC database, increased from 2010 to 2019. The demographics and clinical characteristics were similar in both cohorts over the assessment duration.

摘要

简介

尽管哮喘的患病率和负担不断增加,但日本中度至重度哮喘的情况仍缺乏证据。在这里,我们利用 JMDC 理赔数据库报告了 2010 年至 2019 年中度至重度哮喘的患病率,并描述了患者的人口统计学和临床特征。

方法

在索引年内,JMDC 数据库中≥12 岁的患者,每个索引年内有≥2 次在不同月份确诊的哮喘,根据哮喘预防和管理指南(日本哮喘指南,JGL)或全球哮喘倡议(GINA)的定义将其分为中度至重度哮喘。

主要目标

2010 年至 2019 年中度至重度哮喘患病率的 10 年趋势。

次要目标

2010 年至 2019 年患者的人口统计学和临床特征。

结果

在 JMDC 数据库的 7493027 名患者中,截至 2019 年,有 38089 名和 133557 名患者分别纳入 JGL 和 GINA 队列。两个队列的中度至重度哮喘患病率均呈现从 2010 年到 2019 年增加的趋势,与年龄组无关。在每个日历年内,两个队列的人口统计学和临床特征在各个队列中都是一致的。在 JGL(86.6%)和 GINA(84.2%)队列中,大多数患者年龄在 18-60 岁之间。过敏性鼻炎是最常见的合并症,而在两个队列中均报告了过敏反应是最不常见的合并症。

结论

在 JMDC 数据库中,根据 JGL 或 GINA,日本中度至重度哮喘患者的患病率从 2010 年到 2019 年增加。在评估期间,两个队列的人口统计学和临床特征相似。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验